Clinical trials: COPD Patients
COPD
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
- Trial name
- NCT07116915
- Testing
- HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study of RC1416 Injection in COPD
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07402551
- Testing
- RC1416
- Where
- 46 sites in China
- Volunteers
- 180 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
The goal of this study is to learn if a new formulation of Budesonide/Formoterol Inhalation Powder (160μg/4.5μg), manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd., works the same as the already approved reference…
- Trial name
- BF-BE (NCT07804303)
- Testing
- Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test), Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- EMBARK (NCT06883305)
- Testing
- Tezepelumab
- Where
- 305 sites in United States, Brazil and 16 more
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent Exacerbations in Moscow
This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow
- Trial name
- CERERA-MOSCOW (NCT07307781)
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
COPD, Smoking
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory…
- Conditions
- COPD, Smoking, Tobacco Use
- Trial name
- NCT07108166
- Testing
- Cigarette, THS
- Where
- 112 sites in United States, Bulgaria and 7 more
- Volunteers
- 290 people
- Sponsor
- Philip Morris Products S.A.
COPD
A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.
- Trial name
- NCT07640451
- Testing
- HRS-9821 Inhalation Suspension
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy, Healthy Smoker
Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease
This is a 4-part, randomised, double-blind, placebo-controlled, first in human study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of inhaled RB042.
- Conditions
- Healthy, Healthy Smoker, COPD (Chronic Obstructive Pulmonary Disease), COPD
- Trial name
- NCT07285122
- Testing
- RB042
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Atisama Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation…
- Trial name
- NCT06748079
- Testing
- TQC3721 inhalation powder, TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COPD Exacerbation
Early Detection of COPD Exacerbations Using Home Monitoring Device
The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age >21) with physician-diagnosed COPD who are at…
- Trial name
- NCT07554352
- Testing
- RespirAI
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- RespirAI US Inc
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of…
- Trial name
- MIRANDA (NCT06040086)
- Testing
- Tozorakimab
- Where
- 368 sites in United States, Argentina and 27 more
- Volunteers
- 1,454 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in…
- Trial name
- NCT07288554
- Testing
- BBT002
- Where
- 11 sites in China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
MoblO2 to Maintain Oxygenation
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course.
- Trial name
- SSeifert (NCT07704567)
- Testing
- MoblO2 controls O2 flow, MoblO2 does not control flow
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Minnesota HealthSolutions
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD (Chronic Obstructive Pulmonary Disease)
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)
Primary Objective To demonstrate the superiority of CHF 5993 pressurised metered dose inhaler (pMDI) over Symbicort® Turbuhaler® in terms of pulmonary function (change from baseline in pre-dose morning forced expiratory volume in…
- Trial name
- TRIVERSYTI (NCT03197818)
- Testing
- CHF 5993 100/6/12.5 µg, 160 µg budesonide + 4.5 µg formoterol fumarate
- Where
- 64 sites in China, South Korea and 1 more
- Volunteers
- 708 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation administered in a single dose in healthy individuals and multiple doses in patients with COPD。
- Trial name
- NCT07567872
- Testing
- HRS-9821 Powder for Inhalation
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or…
- Trial name
- COMETA (NCT06897748)
- Testing
- Tozorakimab
- Where
- 12 sites in Russia
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Cancer, Liver Cirrhosis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign…
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B
- Trial name
- ELITE (NCT05181826)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Chronic Obstructive Pulmonary Disease, COPD
Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD
The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.
- Trial name
- NCT05572333
- Testing
- EP395
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 61 people
- Sponsor
- EpiEndo Pharmaceuticals